Thermo Fisher Scientific Inc. is set to acquire data management firm Clario for up to $9.4 billion, marking a significant portfolio expansion. This announcement follows the company's impressive quarterly revenue of $11.12 billion, up 4.9% year-on-year, which exceeded analyst expectations by 1.9%. Bank of America has responded positively by raising its price target for Thermo Fisher stock to $700, reflecting strong market confidence in its growth prospects. Despite slight recent declines, analysts maintain a 'Strong Buy' rating on the stock.
“Thermo Fisher · reported revenues of · $11.12 billion · up 4.9% year on year”
“Thermo Fisher · surpassed analysts’ expectations by · 1.9%”
“Thermo Fisher Scientific Inc. · is listed as · Free Stock Analysis Report · TMO”
“Thermo Fisher Scientific Inc. · is included among · 14 Best Pharma Dividend Stocks to Buy in 2026 · true”
“Bank of America · raised its price target on · Thermo Fisher Scientific Inc. · $700 from $650”
“Thermo Fisher Scientific Inc. · said it would acquire · privately held data management company Clario · up to $9.4 billion”
“Thermo Fisher Scientific Inc. · operates as · a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, and laboratory, pharmaceutical, and biotechnology services · true”
“Thermo Fisher · reported revenues of · $11.12 billion · up 4.9% year on year”
“Thermo Fisher · surpassed analysts’ expectations by · 1.9%”
“Thermo Fisher Scientific Inc. · is identified as · TMO · Free Stock Analysis Report”
“THERMO FISHER SCIENTIFIC INC · rates highest · P/B Growth Investor model · 66%”
“THERMO FISHER SCIENTIFIC INC · is a · large-cap growth stock · Medical Equipment & Supplies industry”
